The Impact of Bariatric Surgery on Nonalcoholic Steatohepatitis

Charlotte Rabl; Guilherme M. Campos

doi:10.1055/s-0032-1306428

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2012; 32(01): 080-091
DOI: 10.1055/s-0032-1306428

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Impact of Bariatric Surgery on Nonalcoholic Steatohepatitis

Authors

Charlotte Rabl

¹Department of Surgery, Paracelsus Private Medical University, Salzburg, Austria
Guilherme M. Campos

²University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Abstract

Nonalcoholic steatohepatitis (NASH) is a stage of nonalcoholic fatty liver disease (NAFLD), and in most patients, is associated with obesity and the metabolic syndrome. The current best treatment of NAFLD and NASH is weight reduction with the current options being life style modifications, with or without pharmaceuticals, and bariatric surgery. Bariatric surgery is an effective treatment option for individuals who are severely obese (body mass index ≥ 35 kg/m²), and provides for long-term weight loss and resolution of obesity-associated diseases in most patients. Regression and/or histologic improvement of NASH have been documented after bariatric surgery. We review the available literature reporting on the impact of the various bariatric surgery techniques on NASH.

Keywords

Nonalcoholic steatohepatitis - nonalcoholic fatty liver disease - obesity - bariatric surgery - weight loss

Full Text

References

References
1 Kowdley KV, Caldwell S. Nonalcoholic steatohepatitis: a twenty-first century epidemic?. J Clin Gastroenterol 2006; 40 (Suppl 1) S2-S4
2 McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 (Suppl 1) S17-S29
3 Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004; 40 (2) 475-483
4 McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8 (3) 521-533 , viii
5 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116 (6) 1413-1419
6 Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 (Suppl 1) S11-S16
7 Maheshwari A, Thuluvath PJ. Cryptogenic cirrhosis and NAFLD: are they related?. Am J Gastroenterol 2006; 101 (3) 664-668
8 Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40 (4) 578-584
9 Hui JM, Kench JG, Chitturi S , et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38 (2) 420-427
10 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346 (16) 1221-1231
11 Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 (Suppl 1) S5-S10
12 Ong JP, Elariny H, Collantes R , et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005; 15 (3) 310-315
13 Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42 (5) 987-1000
14 Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21 (1) 27-41
15 Neuschwander-Tetri BA. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2002; 4 (1) 31-36
16 Campos GM, Bambha K, Vittinghoff E , et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 2008; 47 (6) 1916-1923
17 Anty R, Iannelli A, Patouraux S , et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010; 32 (11–12) 1315-1322
18 Sumida Y, Yoneda M, Hyogo H , et al; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46 (2) 257-268
19 Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol 2009; 8 (Suppl 1) S51-S59
20 Rafiq N, Younossi ZM. Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28 (4) 427-433
21 Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; (1) CD007340
22 Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010; 11 (6) 430-445
23 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49 (1) 306-317
24 Steinbrook R. Surgery for severe obesity. N Engl J Med 2004; 350 (11) 1075-1079
25 Padwal R, Klarenbach S, Wiebe N , et al. Bariatric surgery: a systematic review of the clinical and economic evidence. J Gen Intern Med 2011; 26 (10) 1183-1194
26 Ali MR, Fuller WD, Choi MP, Wolfe BM. Bariatric surgical outcomes. Surg Clin North Am 2005; 85 (4) 835-852 , vii
27 Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007; 142 (4) 621-632 , discussion 632–635
28 Campos GM, Ciovica R, Rogers SJ , et al. Spectrum and risk factors of complications after gastric bypass. Arch Surg 2007; 142 (10) 969-975 , discussion 976
29 Salem L, Jensen CC, Flum DR. Are bariatric surgical outcomes worth their cost? A systematic review. J Am Coll Surg 2005; 200 (2) 270-278
30 Buchwald H, Estok R, Fahrbach K , et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122 (3) 248-256 , e5
31 Nguyen NT, Goldman C, Rosenquist CJ , et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg 2001; 234 (3) 279-289 , discussion 289–291
32 Karlsson J, Taft C, Rydén A, Sjöström L, Sullivan M. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes (Lond) 2007; 31 (8) 1248-1261
33 Buchwald H, Avidor Y, Braunwald E , et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292 (14) 1724-1737
34 Sjöström L, Lindroos AK, Peltonen M , et al; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351 (26) 2683-2693
35 Christou NV, Sampalis JS, Liberman M , et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004; 240 (3) 416-423 , discussion 423–424
36 Adams TD, Gress RE, Smith SC , et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357 (8) 753-761
37 Sjöström L, Narbro K, Sjöström CD , et al; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357 (8) 741-752
38 Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995; 104 (1) 23-31
39 Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 2005; 13 (7) 1180-1186
40 Mattar SG, Velcu LM, Rabinovitz M , et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242 (4) 610-617 , discussion 618–620
41 Mottin CC, Moretto M, Padoin AV , et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obes Surg 2005; 15 (6) 788-793
42 Klein S, Mittendorfer B, Eagon JC , et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006; 130 (6) 1564-1572
43 Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006; 101 (2) 368-373
44 Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obes Surg 2006; 16 (5) 607-611
45 de Almeida SR, Rocha PR, Sanches MD , et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 2006; 16 (3) 270-278
46 Furuya Jr CK, de Oliveira CP, de Mello ES , et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 2007; 22 (4) 510-514
47 Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg 2007; 17 (4) 486-492
48 Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 2010; 28 (1) 274-279
49 Moretto M, Kupski C, da Silva VD, Padoin AV, Mottin CC. Effect of bariatric surgery on liver fibrosis. Obes Surg 2011;
50 Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006; 16 (10) 1278-1286
51 Mathurin P, Hollebecque A, Arnalsteen L , et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137 (2) 532-540
52 Kral JG, Thung SN, Biron S , et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135 (1) 48-58
53 Keshishian A, Zahriya K, Willes EB. Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months. Obes Surg 2005; 15 (10) 1418-1423
54 Ranløv I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 1990; 47 (4) 208-214
55 Luyckx FH, Desaive C, Thiry A , et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22 (3) 222-226
56 Stratopoulos C, Papakonstantinou A, Terzis I , et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005; 15 (8) 1154-1160
57 Jaskiewicz K, Raczynska S, Rzepko R, Sledziński Z. Nonalcoholic fatty liver disease treated by gastroplasty. Dig Dis Sci 2006; 51 (1) 21-26
58 Gastrointestinal surgery for severe obesity. NIH consensus development conference, March 25-7,1991. Nutrition 1996; 12 (6) 397-404
59 U.S. Food and Drug Administration. FDA expands use of banding system for weight loss. February 16, 2011 News release. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm245617.htm . Accessed December 4, 2011
60 Gould J, Ellsmere J, Fanelli R , et al. Panel report: best practices for the surgical treatment of obesity. Surg Endosc 2011; 25 (6) 1730-1740
61 Campos GM, Rabl C, Roll GR , et al. Better weight loss, resolution of diabetes, and quality of life for laparoscopic gastric bypass vs banding: results of a 2-cohort pair-matched study. Arch Surg 2011; 146 (2) 149-155
62 Flum DR, Belle SH, King WC , et al; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361 (5) 445-454
63 Tice JA, Karliner L, Walsh J, Petersen AJ, Feldman MD. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med 2008; 121 (10) 885-893
64 Vetter ML, Vinnard CL, Wadden TA. Perioperative safety and bariatric surgery. N Engl J Med 2009; 361 (19) 1910 , author reply 1911
65 Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149 (11) 981-983
66 DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med 2007; 356 (21) 2176-2183
67 Buchwald H ; Consensus Conference Panel. Consensus conference statement bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. Surg Obes Relat Dis 2005; 1 (3) 371-381
68 Cunneen SA. Review of meta-analytic comparisons of bariatric surgery with a focus on laparoscopic adjustable gastric banding. Surg Obes Relat Dis 2008; 4 (3, Suppl) S47-S55
69 Gagner M, Milone L, Yung E, Broseus A, Gumbs AA. Causes of early mortality after laparoscopic adjustable gastric banding. J Am Coll Surg 2008; 206 (4) 664-669
70 Buchwald H, Williams SE. Bariatric surgery training in the United States. Surg Obes Relat Dis 2006; 2 (1) 52-55 , discussion 55–56
71 Himpens J, Cadière GB, Bazi M, Vouche M, Cadière B, Dapri G. Long-term outcomes of laparoscopic adjustable gastric banding. Arch Surg 2011; 146 (7) 802-807
72 Nguyen NT, Sloan J, Nguyen XM. Laparoscopic gastric bypass or gastric banding: which operation is best?. Adv Surg 2010; 44: 49-57
73 Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for obesity. Cochrane Database Syst Rev 2009; (2) CD003641
74 Kim S, Richards WO. Long-term follow-up of the metabolic profiles in obese patients with type 2 diabetes mellitus after Roux-en-Y gastric bypass. Ann Surg 2010; 251 (6) 1049-1055
75 de Freitas AC, Campos AC, Coelho JC. The impact of bariatric surgery on nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2008; 11 (3) 267-274
76 Verna EC, Berk PD. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. Semin Liver Dis 2008; 28 (4) 407-426
77 Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28 (4) 396-406
78 Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol 1992; 87 (6) 775-779
79 Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39 (6) 1647-1654
80 Promrat K, Kleiner DE, Niemeier HM , et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51 (1) 121-129
81 Campos GM, Rabl C, Peeva S , et al. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg 2010; 14 (1) 15-23
82 Peterli R, Wölnerhanssen B, Peters T , et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009; 250 (2) 234-241
83 Lee WJ, Chong K, Ser KH , et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 2011; 146 (2) 143-148
84 le Roux CW, Welbourn R, Werling M , et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246 (5) 780-785
85 Small CJ, Bloom SR. Gut hormones as peripheral anti-obesity targets. Curr Drug Targets CNS Neurol Disord 2004; 3 (5) 379-388
86 Patriti A, Facchiano E, Sanna A, Gullà N, Donini A. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 2004; 14 (6) 840-848
87 Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007; 3 (6) 597-601
88 Baggio LL, Drucker DJ. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. Best Pract Res Clin Endocrinol Metab 2004; 18 (4) 531-554
89 Rubino F, Gagner M, Gentileschi P , et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240 (2) 236-242
90 Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132 (6) 2131-2157
91 Pedersen J, Holst JJ. Glucagon like-peptide 1 receptor and the liver. Liver Int 2011; 31 (9) 1243-1245
92 Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137 (7) 2968-2978
93 Klonoff DC, Buse JB, Nielsen LL , et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24 (1) 275-286
94 Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43 (1) 173-181
95 Gupta NA, Mells J, Dunham RM , et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51 (5) 1584-1592
96 Svegliati-Baroni G, Saccomanno S, Rychlicki C , et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011; 31 (9) 1285-1297
97 Neary NM, Small CJ, Bloom SR. Gut and mind. Gut 2003; 52 (7) 918-921
98 Batterham RL, Cowley MA, Small CJ , et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418 (6898) 650-654
99 Batterham RL, Cohen MA, Ellis SM , et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349 (10) 941-948
100 Date Y, Kojima M, Hosoda H , et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141 (11) 4255-4261
101 Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 2003; 138 (4) 389-396
102 Cummings DE, Clement K, Purnell JQ , et al. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 2002; 8 (7) 643-644
103 Purnell JQ, Weigle DS, Breen P, Cummings DE. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab 2003; 88 (12) 5747-5752
104 Cummings DE, Weigle DS, Frayo RS , et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346 (21) 1623-1630
105 Korner J, Bessler M, Cirilo LJ , et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90 (1) 359-365
106 Lin E, Gletsu N, Fugate K , et al. The effects of gastric surgery on systemic ghrelin levels in the morbidly obese. Arch Surg 2004; 139 (7) 780-784
107 Hanusch-Enserer U, Cauza E, Brabant G , et al. Plasma ghrelin in obesity before and after weight loss after laparoscopical adjustable gastric banding. J Clin Endocrinol Metab 2004; 89 (7) 3352-3358
108 Hanusch-Enserer U, Brabant G, Roden M. Ghrelin concentrations in morbidly obese patients after adjustable gastric banding. N Engl J Med 2003; 348 (21) 2159-2160
109 Stoeckli R, Chanda R, Langer I, Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res 2004; 12 (2) 346-350
110 Plum L, Ahmed L, Febres G , et al. Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss. Obesity (Silver Spring) 2011; 19 (11) 2149-2157
111 Swarbrick MM, Austrheim-Smith IT, Stanhope KL , et al. Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia 2006; 49 (11) 2552-2558
112 Swarbrick MM, Stanhope KL, Austrheim-Smith IT , et al. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia 2008; 51 (10) 1901-1911
113 Marantos G, Daskalakis M, Karkavitsas N, Matalliotakis I, Papadakis JA, Melissas J. Changes in metabolic profile and adipoinsular axis in morbidly obese premenopausal females treated with restrictive bariatric surgery. World J Surg 2011; 35 (9) 2022-2030
114 Lima MM, Pareja JC, Alegre SM , et al. Acute effect of Roux-en-Y gastric bypass on whole-body insulin sensitivity: a study with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab 2010; 95 (8) 3871-3875